In today’s Pharmaceutical Executive Daily, Pfizer discloses its 2026 revenue expectations, a bipartisan group of House ...

Novo Nordisk’s NDA filing for CagriSema positions the first fixed-dose amylin–GLP-1 combination as a potential ...

Lilly’s Attain-Maintain Phase III results show that the oral GLP-1 orforglipron can effectively preserve weight loss after injectable therapy, positioning it as a potential long-term maintenance ...

The Biosecure Act aims to prevent federal funding to Chinese biotech companies labeled "of concern" by the Office of Management and Budget or the Department of Defense. A political shift in the House ...

The imminent end of the rebate era means human resources (HR) benefits decision-makers and pharmacy consultants are about to see a paradigm shift. They will need to act quickly to adjust benefits ...